基于网络药理学和分子对接分析灯盏花防治NAFLD的分子靶点和机制

Molecular Targets and Mechanisms of Erigeron Breviscapus in the Prevention and Treatment of NAFLD

基于目前尚未有针对非酒精性脂肪肝的批准药物,以及非酒精性脂肪肝发病率高,造成经济负担重的现状,通过数据库收集NAFLD(非酒精性脂肪肝)以及灯盏花相关疾病靶点,通过网络药理学研究了灯盏乙素可能作用于NAFLD的潜在靶点,进一步通过可视化分析和对hub基因进行富集分析发现,灯盏花中的槲皮素是灯盏花作用于NAFLD的核心成分,AKT1是槲皮素作用于NAFLD的核心靶点,之后采用分子对接方式验证了槲皮素与AKT1结合的可能性,采用网络药理学的方式分析了中药的多种复杂成分作用于NAFLD的可能性,避免了以往传统药理学分析的局限性,为NAFLD的治疗以及灯盏花药用成分的开发提供了新的思路。

Due to the fact that there are no approved drugs for non-alcoholic fatty liver disease, and the high incidence of non-alcoholic fatty liver disease causes a heavy economic burden;We collects NAFLD(non-alcoholic fatty liver disease) and Brevis-related disease targets through the database,The potential targets of scutellarin that may act on NAFLD were Researched by network pharmacology, Through further visualization analysis and enrichment analysis of hub genes;it was found that quercetin in Brevis is the core component of Brevis that acts on NAFLD. AKT1 is the core target of quercetin acting on NAFLD, and then the possibility of quercetin binding to AKT1 was verified by molecular docking. tThe network pharmacology method was used to analyze the possibility of various complex components of traditional Chinese medicine acting on NAFLD, which avoided the limitations of traditional pharmacological analysis, and provided new insights for the treatment of NAFLD and the development of medicinal components of Brevis.